Cargando…

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

BACKGROUND: A pharmacogenomic platform using patient-derived cells (PDCs) was established to identify the underlying resistance mechanisms and tailored treatment for patients with advanced or refractory lung cancer. METHODS: Drug sensitivity screening and multi-omics datasets were acquired from lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Namhee, Hwang, Mihwa, Lee, Youngjoo, Song, Bo Ram, Kang, Eun Hye, Sim, Hanna, Ahn, Beung-Chul, Hwang, Kum Hui, Kim, Jihyun, Hong, Sehwa, Kim, Sunshin, Park, Charny, Han, Ji-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885631/ https://www.ncbi.nlm.nih.gov/pubmed/36717865 http://dx.doi.org/10.1186/s13046-023-02606-3

Ejemplares similares

Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance
por: Kim, Jihyun, et al.
Publicado: (2023)

Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Ataxia-Telangiectasia Mutated Is Involved in Autolysosome Formation
por: Hwang, Mihwa, et al.
Publicado: (2023)

Splicing signature database development to delineate cancer pathways using literature mining and transcriptome machine learning
por: Lee, Kyubin, et al.
Publicado: (2023)

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report
por: Choi, Wonyoung, et al.
Publicado: (2022)

Ouabain, a Cardiac Glycoside, Inhibits the Fanconi Anemia/BRCA Pathway Activated by DNA Interstrand Cross-Linking Agents
por: Wha Jun, Dong, et al.
Publicado: (2013)

EI24, as a Component of Autophagy, Is Involved in Pancreatic Cell Proliferation
por: Hwang, Mihwa, et al.
Publicado: (2019)

DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression
por: Jun, Dong Wha, et al.
Publicado: (2016)

Complexities of pharmacogenomic interactions in cancer
por: Khanna, Kum Kum, et al.
Publicado: (2020)

Applying Pharmacogenomics in Therapeutics
por: Jimenez-Sainz, Judit
Publicado: (2017)

One‐Step Polymerase Chain Reaction‐Free Nanowire‐Based Plasma Cell‐Free DNA Assay to Detect EML4‐ALK Fusion and to Monitor Resistance in Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2021)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Challenges and Opportunities in Pharmacogenomics and Therapeutics
por: Kane, Michael D., et al.
Publicado: (2007)

Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy
por: Roosan, Don, et al.
Publicado: (2020)

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies
por: Hwang, Kyung Won, et al.
Publicado: (2023)

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί
por: Lee, Jeon-Soo, et al.
Publicado: (2021)

Human immunodeficiency virus therapeutics and pharmacogenomics
por: Shankarkumar, U., et al.
Publicado: (2011)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Preclinical Drug Response Metric Based on Cellular Response Phenotype Provides Better Pharmacogenomic Variables with Phenotype Relevance
por: Kim, Sanghyun, et al.
Publicado: (2021)

Analysis of Pharmacogenomic Variants Associated with Population Differentiation
por: Yeon, Bora, et al.
Publicado: (2015)

Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer
por: Kong, Weiqi, et al.
Publicado: (2023)

Pharmacogenomics of Hypersensitivity to Non-steroidal Anti-inflammatory Drugs
por: Trinh, Hoang Kim Tu, et al.
Publicado: (2021)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

The reality of pharmacogenomics: optimizing therapeutic decision making.
por: Lee, Craig R, et al.
Publicado: (2003)

Therapeutic Potential of Differentiated Mesenchymal Stem Cells for Treatment of Osteoarthritis
por: Ham, Onju, et al.
Publicado: (2015)

Comprehensive pharmacogenomic characterization of gastric cancer
por: Sa, Jason K., et al.
Publicado: (2020)

Predicting treatment outcomes using (18)F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
por: Kim, Chang Gon, et al.
Publicado: (2022)

R-catcher, a potent molecular tool to unveil the arginylome
por: Seo, Taewook, et al.
Publicado: (2021)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies
por: Wang, Chun-Hsiang, et al.
Publicado: (2010)

Pharmacogenomics
Publicado: (2008)

Pharmacogenomics
Publicado: (2008)

Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics
por: Agarwal, Aniruddha, et al.
Publicado: (2014)

Pharmacogenetics and pharmacogenomics in glaucoma therapeutics: the way to personalized therapy
por: Liao, Shiyu, et al.
Publicado: (2023)

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013)

Pharmacogenomics and migraine: possible implications
por: Tfelt-Hansen, Peer, et al.
Publicado: (2008)

Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets
por: Kim, Jihyun, et al.
Publicado: (2018)

SMARCA4 Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer
por: Kim, Jihyun, et al.
Publicado: (2021)

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_njren6g8s8bmcu072h2bn0nd0b